

Supplementary materials

Bell's palsy following SARS-CoV-2 vaccines: a systematic review and meta-analysis

Table of Contents

Table S1- Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 Checklist..... 2

Table S2- Systematic search syntax for databases with results as of August 15, 2022. 5

Figure S1- Quality assessment of the Randomized Controlled Trials using the Cochrane Risk of Bias (ROB1) tool. 8

Table S4- Quality assessment of the cohorts using the Newcastle-Ottawa scale (NOS) modified for cohort studies. 9

Table S5- Quality assessment of the case controls using the Newcastle-Ottawa scale (NOS) modified for case control studies. 10

Table S6- Quality assessment of the cross-sectional studies using the Newcastle-Ottawa scale (NOS) modified for cross-sectional studies. 11

Table S7- Quality assessment of the self-controlled cases series studies using the Newcastle-Ottawa scale (NOS) modified for self-controlled cases series studies. 12

Figure S2- Funnel plot for RCTs: vaccinated vs. saline placebo 13

Figure S3- Funnel plot for observational studies on mRNA vaccines: vaccinated vs. unvaccinated. 14

Figure S4- Funnel plot for Pfizer/BioNTech vs. Oxford/AstraZeneca 15

Figure S5- Funnel plot for SARS-CoV-2 infections vs. SARS-CoV-2 vaccine 16

Table S8- Data extraction table. 17

Table S9- Summary of the studies' characteristics (case reports and case series). 36

Table S1- Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported (page No.)
TITLE			
Title	1	Identify the report as a systematic review.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	3
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	4
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	4
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	4
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	5
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	5
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	5
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	5
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	5,6
Synthesis	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention	5,6

Section and Topic	Item #	Checklist item	Location where item is reported (page No.)
methods		characteristics and comparing against the planned groups for each synthesis (item #5)).	
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	5
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	5
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	5
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	6
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	-
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	-
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	-
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	6
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	6,7
Study characteristics	17	Cite each included study and present its characteristics.	7
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	7
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	7,8
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	7,8
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	7,8
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	-
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	-
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	-

Section and Topic	Item #	Checklist item	Location where item is reported (page No.)
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	-
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	8, 9
	23b	Discuss any limitations of the evidence included in the review.	9, 10
	23c	Discuss any limitations of the review processes used.	9, 10
	23d	Discuss implications of the results for practice, policy, and future research.	10
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	4
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	4
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	-
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	11
Competing interests	26	Declare any competing interests of review authors.	11
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	11

Table S2- Systematic search syntax for databases with results as of August 15, 2022.

MEDLINE (via Pubmed)		
No.	Syntax	No. of results
1.	((("COVID-19"[Title/Abstract] OR "sars cov 2"[Title/Abstract] OR "covid 19 vaccines"[Title/Abstract] OR "covid 19 vaccines"[MeSH Terms] OR "covid 19 vaccine*"[Title/Abstract] OR "sars cov 2 vaccine*"[Title/Abstract] OR "sars cov 2 vaccine*"[Title/Abstract] OR "vaccines sars cov 2"[Title/Abstract]))	267,371
2.	("Bell Palsy"[MeSH Terms]) OR ((Palsies[Title/Abstract] AND Bell[Title/Abstract])) OR ("Bell Palsy"[Title/Abstract]) OR ((Palsy[Title/Abstract] AND Bell[Title/Abstract])) OR ((Facial Paralysis[Title/Abstract] AND Idiopathic[Title/Abstract])) OR ((Facial Paralysis[Title/Abstract] AND Idiopathic[Title/Abstract])) OR ("Idiopathic Facial Paralysis"[Title/Abstract]) OR ("Idiopathic Facial Paralysis"[Title/Abstract]) OR ((Paralyses[Title/Abstract] AND "Idiopathic Facial"[Title/Abstract])) OR ((("Inflammatory Facial Neuropathy"[Title/Abstract] AND Acute[Title/Abstract])) OR ("Acute Inflammatory Facial Neuropathy"[Title/Abstract]) OR ("Idiopathic Acute Facial Neuropathy"[Title/Abstract]) OR ("Bell's Palsy"[Title/Abstract]) OR ("Bell's Palsies"[Title/Abstract]) OR ("Herpetic Facial Paralysis"[Title/Abstract]) OR ((Paralyses[Title/Abstract] AND "Herpetic Facial"[Title/Abstract])) OR ("Facial Paralysis"[Title/Abstract]) OR ((Paralyses[Title/Abstract] AND Facial[Title/Abstract])) OR ((Paralysis[Title/Abstract] AND Facial[Title/Abstract])) OR ("Facial Palsy"[Title/Abstract]) OR ("Facial Palsies"[Title/Abstract]) OR ("Hemifacial Paralysis"[Title/Abstract]) OR ((Paralyses[Title/Abstract] AND Hemifacial[Title/Abstract])) OR ("Facial Paresis"[Title/Abstract]) OR ("Lower Motor Neuron Facial Palsy"[Title/Abstract]) OR ((("Facial Paralysis"[Title/Abstract] AND Peripheral[Title/Abstract])) OR ((("Facial Paralysis"[Title/Abstract] AND Peripheral[Title/Abstract])) OR ((Paralysis[Title/Abstract] AND "Peripheral Facial"[Title/Abstract]))	14,929
3.	#1 AND #2	207


Web of Science		
No.	Syntax	No. of results
1.	((((TI=COVID-19 OR AB=COVID-19) OR (TI="sars cov 2" OR AB="sars cov 2") OR (TI="covid 19 vaccines" OR AB="covid 19 vaccines") OR ALL="covid 19 vaccines" OR (TI="covid 19 vaccine*" OR AB="covid 19 vaccine*") OR (TI="sars cov 2 vaccine*" OR AB="sars cov 2 vaccine*") OR (TI="sars cov 2 vaccine*" OR AB="sars cov 2 vaccine*") OR (TI="vaccines sars cov 2" OR AB="vaccines sars cov 2"))	314,012
2.	(ALL="Bell Palsy") OR (((TI=Palsies OR AB=Palsies) AND (TI=Bell OR AB=Bell)))OR ((TI="Bell Palsy" OR AB="Bell Palsy")) OR (((TI=Palsy OR AB=Palsy) AND (TI=Bell OR AB=Bell))) OR (((TI="Facial Paralysis" OR AB="Facial Paralysis") AND (TI=Idiopathic OR AB=Idiopathic))) OR (((TI="Facial Paralysis" OR AB="Facial Paralysis") AND (TI=Idiopathic OR AB=Idiopathic))) OR ((TI="Idiopathic Facial Paralysis" OR AB="Idiopathic Facial Paralysis")) OR ((TI="Idiopathic Facial Paralysis" OR AB="Idiopathic Facial Paralysis")) OR (((TI=Paralyses OR AB=Paralyses) AND (TI="Idiopathic Facial" OR AB="Idiopathic Facial"))) OR (((TI="Inflammatory Facial Neuropathy" OR AB="Inflammatory Facial Neuropathy") AND (TI=Acute OR	10,374

	AB=Acute))) OR ((TI="Acute Inflammatory Facial Neuropathy" OR AB="Acute Inflammatory Facial Neuropathy")) OR ((TI="Idiopathic Acute Facial Neuropathy" OR AB="Idiopathic Acute Facial Neuropathy")) OR ((TI="Bell's Palsy" OR AB="Bell's Palsy")) OR ((TI="Bell's Palsies" OR AB="Bell's Palsies")) OR ((TI="Herpetic Facial Paralysis" OR AB="Herpetic Facial Paralysis")) OR (((TI=Paralyses OR AB=Paralyses) AND (TI="Herpetic Facial" OR AB="Herpetic Facial"))) OR ((TI="Facial Paralysis" OR AB="Facial Paralysis")) OR (((TI=Paralyses OR AB=Paralyses) AND (TI=Facial OR AB=Facial))) OR (((TI=Paralysis OR AB=Paralysis) AND (TI=Facial OR AB=Facial))) OR ((TI="Facial Palsy" OR AB="Facial Palsy")) OR ((TI="Facial Palsies" OR AB="Facial Palsies")) OR ((TI="Hemifacial Paralysis" OR AB="Hemifacial Paralysis")) OR (((TI=Paralyses OR AB=Paralyses) AND (TI=Hemifacial OR AB=Hemifacial))) OR ((TI="Facial Paresis" OR AB="Facial Paresis")) OR ((TI="Lower Motor Neuron Facial Palsy" OR AB="Lower Motor Neuron Facial Palsy")) OR (((TI="Facial Paralysis" OR AB="Facial Paralysis") AND (TI=Peripheral OR AB=Peripheral))) OR (((TI="Facial Paralyses" OR AB="Facial Paralyses") AND (TI=Peripheral OR AB=Peripheral))) OR (((TI=Paralysis OR AB=Paralysis) AND (TI="Peripheral Facial" OR AB="Peripheral Facial"))))	
3.	#1 AND #2	190

Scopus		
No.	Syntax	No. of results
1.	((TITLE-ABS(COVID-19) OR TITLE-ABS("sars cov 2") OR TITLE-ABS("covid 19 vaccines") OR INDEXTERMS("covid 19 vaccines") OR TITLE-ABS("covid 19 vaccine*") OR TITLE-ABS("sars cov 2 vaccine*") OR TITLE-ABS("sars cov 2 vaccine*") OR TITLE-ABS("vaccines sars cov 2"))))	343,584
2.	(INDEXTERMS("Bell Palsy")) OR ((TITLE-ABS(Palsies) AND TITLE-ABS(Bell)))OR (TITLE-ABS("Bell Palsy")) OR ((TITLE-ABS(Palsy) AND TITLE-ABS(Bell))) OR ((TITLE-ABS("Facial Paralysis") AND TITLE-ABS(Idiopathic))) OR ((TITLE-ABS("Facial Paralyses") AND TITLE-ABS(Idiopathic))) OR (TITLE-ABS("Idiopathic Facial Paralyses")) OR (TITLE-ABS("Idiopathic Facial Paralysis")) OR ((TITLE-ABS(Paralyses) AND TITLE-ABS("Idiopathic Facial"))) OR ((TITLE-ABS("Inflammatory Facial Neuropathy") AND TITLE-ABS(Acute))) OR (TITLE-ABS("Acute Inflammatory Facial Neuropathy")) OR (TITLE-ABS("Idiopathic Acute Facial Neuropathy")) OR (TITLE-ABS("Bell's Palsy")) OR (TITLE-ABS("Bell's Palsies")) OR (TITLE-ABS("Herpetic Facial Paralysis")) OR ((TITLE-ABS(Paralyses) AND TITLE-ABS("Herpetic Facial"))) OR (TITLE-ABS("Facial Paralysis")) OR ((TITLE-ABS(Paralyses) AND TITLE-ABS(Facial))) OR ((TITLE-ABS(Paralysis) AND TITLE-ABS(Facial))) OR (TITLE-ABS("Facial Palsy")) OR (TITLE-ABS("Facial Palsies")) OR (TITLE-ABS("Hemifacial Paralysis")) OR ((TITLE-ABS(Paralyses) AND TITLE-ABS(Hemifacial))) OR (TITLE-ABS("Facial Paresis")) OR (TITLE-ABS("Lower Motor Neuron Facial Palsy")) OR ((TITLE-ABS("Facial Paralysis") AND TITLE-ABS(Peripheral))) OR ((TITLE-ABS("Facial Paralyses") AND TITLE-ABS(Peripheral))) OR ((TITLE-ABS(Paralysis) AND TITLE-ABS("Peripheral Facial"))))	18,531
3.	#1 AND #2	247

Cochrane library		
No.	Syntax	No. of results
1.	((COVID-19:ti,ab OR "sars cov 2":ti,ab OR "covid 19 vaccines":ti,ab OR [mh "covid 19 vaccines"] OR ("covid 19" NEXT vaccine*):ti,ab OR ("sars cov 2" NEXT vaccine*):ti,ab OR ("sars cov 2" NEXT vaccine*):ti,ab OR "vaccines sars cov 2":ti,ab))	11,123
2.	([mh "Bell Palsy"]) OR ((Palsies:ti,ab AND Bell:ti,ab))OR ("Bell Palsy":ti,ab) OR ((Palsy:ti,ab AND Bell:ti,ab)) OR (("Facial Paralysis":ti,ab AND Idiopathic:ti,ab)) OR (("Facial Paralyses":ti,ab AND Idiopathic:ti,ab)) OR ("Idiopathic Facial Paralyses":ti,ab) OR ("Idiopathic Facial Paralysis":ti,ab) OR ((Paralyses:ti,ab AND "Idiopathic Facial":ti,ab)) OR (("Inflammatory Facial Neuropathy":ti,ab AND Acute:ti,ab)) OR ("Acute Inflammatory Facial Neuropathy":ti,ab) OR ("Idiopathic Acute Facial Neuropathy":ti,ab) OR ("Bell's Palsy":ti,ab) OR ("Bell's Palsies":ti,ab) OR ("Herpetic Facial Paralysis":ti,ab) OR ((Paralyses:ti,ab AND "Herpetic Facial":ti,ab)) OR ("Facial Paralysis":ti,ab) OR ((Paralyses:ti,ab AND Facial:ti,ab)) OR ((Paralysis:ti,ab AND Facial:ti,ab)) OR ("Facial Palsy":ti,ab) OR ("Facial Palsies":ti,ab) OR ("Hemifacial Paralysis":ti,ab) OR ((Paralyses:ti,ab AND Hemifacial:ti,ab)) OR ("Facial Paresis":ti,ab) OR ("Lower Motor Neuron Facial Palsy":ti,ab) OR (("Facial Paralysis":ti,ab AND Peripheral:ti,ab)) OR (("Facial Paralyses":ti,ab AND Peripheral:ti,ab)) OR ((Paralysis:ti,ab AND "Peripheral Facial":ti,ab))	808
3.	#1 AND #2	4

Figure S1- Quality assessment of the Randomized Controlled Trials using the Cochrane Risk of Bias (ROB1) tool.



D1: Selection bias Random sequence generation
 D2: Selection bias Allocation concealment
 D3: Reporting bias Selective reporting
 D4: Performance bias Blinding participants and personnel
 D5: Detection bias Blinding outcome assessment
 D6: Attrition bias Incomplete outcome data
 D7: Other bias Other sources of bias

Judgement
 Low
 Unclear
 High
 Critical




Table S4- Quality assessment of the cohorts using the Newcastle-Ottawa scale (NOS) modified for cohort studies.

<i>Study</i>	<i>Selection (Maximum 4 stars)</i>				<i>Comparability (Maximum 2 star)</i>	<i>Outcome (Maximum 3 stars)</i>			<i>Total scores</i>
	Representativeness of the exposed cohort	Selection of the nonexposed cohort :	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy for follow-up of cohorts	
<i>Barda et al.</i>	*	*	*	*	**	*	*	*	9
<i>Bardenheier et al.</i>	*		*	*	*	*	*	*	7
<i>Davidov et al.</i>			*		*		*	*	4
<i>Filippatos et al.</i>			*	*		*	*	*	5
<i>Frontera et al.</i>	*	*	*			*	*	*	6
<i>Klein et al.</i>	*	*	*		**	*	*	*	8
<i>Koh et al.</i>	*	*	*	*		*	*	*	7
<i>Lai et al. (adolescent)</i>		*	*	*	*	*	*		7
<i>Lai et al. (adult)</i>	*	*	*	*	*	*	*		7
<i>Li et al.</i>	*	*	*		*	*	*	*	7
<i>McMurry et al.</i>	*	*	*	*	**	*	*	*	9
<i>Nosedo et al.</i>	*	*	*			*			4
<i>Patone et al.</i>	*	*	*	*	*	*	*	*	8
<i>Shasha et al.</i>	*	*	*		**	*	*	*	8
<i>Shibli et al.</i>	*	*	*	*	*	*	*	*	8
<i>Tan et al.</i>		*	*		**	*		*	6

Table S5- Quality assessment of the case controls using the Newcastle-Ottawa scale (NOS) modified for case control studies.

Study	Selection: (Maximum 4 stars)			Comparability: (Maximum 2 stars)	Exposure: (Maximum 3 stars)			Total scores
	Is the case definition adequate?	Representativeness of the cases	Selection of Controls		Definition of Controls	Ascertainment of exposure	Same method of ascertainment for cases and controls	
Shemer et al.	*	*		*	**	*	*	7
Wan et al.	*	*		*	**	*	*	8

Table S6- Quality assessment of the cross-sectional studies using the Newcastle-Ottawa scale (NOS) modified for cross-sectional studies.

Study *Selection: (Maximum 5 stars)* *Comparability: (Maximum 2 stars)* *Outcome: (Maximum 3 stars)*

	Representativeness of the sample	Sample size	Non-respondents	Ascertainment of the exposure (risk factor):	The subjects in different outcome groups are comparable, based on the study design or analysis. Confounding factors are controlled	Assessment of the outcome	Statistical test	Total scores
<i>El-Shitany et al.</i>				*		*	*	3
<i>Hüls et al.</i>	*					*	*	3
<i>Tamaki et al.</i>	*	*		*	*	*	*	6

Table S7- Quality assessment of the self-controlled cases series studies using the Newcastle-Ottawa scale (NOS) modified for self-controlled cases series studies.

Study	Selection: (Maximum 3 stars)			Comparability: (Maximum 2 stars)	Outcome: (Maximum 5 stars)				Total scores	
	Representativeness of the cases	Ascertainment of exposure	Demonstration that outcome of interest was not present at the start of the study	Comparability of cases on the basis of the design of analysis	Assessment of outcome	Risk period stated	Control period stated	Risk period and control period long enough for outcomes to occur?		Adequacy of follow-up of cases
Walker et al.	*	*	*	**	*	*	*			8
Ab Rahman et al.	*	*	*	**	*	*	*	*		9

Figure S2- Funnel plot for RCTs: vaccinated vs. saline placebo




Figure S3- Funnel plot for observational studies on mRNA vaccines: vaccinated vs. unvaccinated




Figure S4- Funnel plot for Pfizer/BioNTech vs. Oxford/AstraZeneca




Figure S5- Funnel plot for SARS-CoV-2 infections vs. SARS-CoV-2 vaccine




Table S8- Data extraction table.

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2- vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-coV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Parademics	Treatment	Outcome	Recurrence
El Sahly 2021	RCT	Mod / 1 or 2	placebo group (saline)	14,287/28,451 (50.2%)	51.3 (18-95) *	Vaccinated: 6,848 (48%)	no	NA	Vaccinated: 8 (<0.1%)	Bell's palsy	NA	NA	NA	1 or 2	NA	NA	NA	NA	NA	NA	NA	NA	NA
						Placebo: 6,670 (48%)			Placebo: 3 (<0.1%)														
Sadoff 2022	RCT	Jn / 1	placebo group (saline)	21,898/43,788 (50%)	52.0 (18-100) †	Vaccinated: 9,828 (44.9%)	no	NA	Vaccinated: 2 (<0.1%)	Bell's palsy	NA	NA	NA	1	3 and 16 days after vaccination	NA	NA	NA	NA	NA	NA	NA	NA
						Placebo: 9,907 (45.3%)			Placebo: 1 (<0.1%)														
Thomass 2021	RCT	PfiB / 1 or 2	placebo group (saline)	22,026/44,047 (50%)	51.0 (16-91) †	Vaccinated, 10,704 (48.6%)	364 (<0.1%)	NA	Vaccinated: 4 (<0.1%)	Bell's palsy	NA	NA	NA	1 or 2	3, 9, 37, and 48 days after vaccination	NA	NA	NA	NA	NA	NA	NA	NA
						Placebo: 10,923 (49.6%)			Placebo: 0														
Falsey 2021	RCT	OxAz/ 1 or 2	placebo group (saline)	21,635/32,451 (66.66%)	51.0 (18-100) †	Vaccinated 9,575(44.4%)	vaccine group: 623(2.9%); placebo group 292(2.7%)	NA	Vaccinated: 1 (<0.1%)	facial paralysis	NA	NA	NA	1 or 2	NA	NA	NA	NA	NA	NA	NA	NA	NA
						Placebo: 4,789(44.4%)			Placebo: 0														
Voysey 2021	RCT	OxAz/ 1 or 2	placebo group (meningococcal group A, C, W, and Y conjugate vaccine or	12,082/23,848 (50.67%)	NA ‡	varied between trials- females form the majority	no	no	Vaccinated: 3 (<0.1%)	facial paralysis	NA	NA	NA	1 or 2	NA	NA	NA	NA	NA	NA	NA	NA	NA
									Placebo: 3 (<0.1%)														

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paradigns	Treatment	Outcome	Recurrence
														30 days									
Bardenheier 2021	cohort	PfIB) / 1 or 2; Mod / 1 or 2	unvaccinated cases	10,356/21,215 (48.8%)	NA ¶	13,123 (61.9%)	N/A	N/A	1 (0.01%)	Bell's palsy	NA	NA	NA	1	11 days	N/A	NA	AF, COPD, ICH, TIA, CVA, vascular dementia, seizure, MDD, DLP, HTN, peripheral vascular disease, osteoporosis, GERD, and hypothyroidism	NA	NA	NA	NA	NA
Koh 2021	cohort	PfIB / 1 or 2	none	1,398,074/1,398,074 (100%)	59 (15–121) §	636,124 (45.5%)	NA	NA	11 (2.4%)	Bell's Palsy	NA	NA	NA	6 after dose 1 (PfIB) / 5 after dose 2 (PfIB)	median (range): 7 (1–29) days		NA	NA	NA	NA	NA	6 (54.5%) patients partial recovery within 1–2 months; 1 (9.1%) fully recovered at 3 months, 4 (36.4%) patients: NA.	NA
Patone 2021	cohort#	PfIB / 1; OxAz / 1	SARS-CoV-2 infection	34,557,814/34,557,814 (100%)	PfIB: 55.9 (20.1) OxAz: 55.1 (14.8)	PfIB: 6,608,730 (57%) OxAz: 10,150,568 (52.3%)	2,005,280 (~6%) in the SARS-CoV-2 infection group	NA	PfIB: 250 (<0.01%) OxAz: 435 (<0.01%)	Bell's palsy	NA	NA	NA	1	NA	NA	NA	NA	NA	NA	NA	NA	NA
Li 2022	cohort#	OxAz/ 1 or 2; PfIB / 1 or 2	general population - other SARS-CoV-2 vaccines	4,497,003/4,678,512 (96.1%)	47 (36–63) §	2,391,109 (51.1%)	204,798 (45.8%)	NA	247 (<0.1%)	Bell's palsy	NA	NA	NA	OxAz / 1: 27, 2: 10; PfIB / 1: 100, 2: 85;	NA	NA	NA	multiple comorbidities of which most prevalent were	NA	NA	NA	NA	NA

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paradigns	Treatment	Outcome	Recurrence	
		2; Mod / 1 or 2; Jn / 1												Mod / 1:14, 2: 5; Jn / 1: 6				hypertension and obesity						
Lai 2022 (adults)	cohort	PfiB / 1; CoronaVac / 1	unvaccinated	335,620/883,416 (38%)	PfiB: 56.81 (13.43)	PfiB: 80,592 (52.6%)	NA	NA	PfiB: 4 (<0.1%)	Bell's palsy	NA	NA	NA	1	NA		NA	multiple comorbidities of which most prevalent were hypertension (67.1%) and type 2 diabetes mellitus (33%)	NA	NA	NA	NA	NA	
					Corona Vac: 61.58 (11.08)	Corona Vac: 93,561 (51.3%)			Corona Vac: 9 (<0.1%)															
					Unvaccinated: 62.11 (12.85)	Unvaccinated: 318,005 (58.1%)			Unvaccinated: 24 (<0.1%)															
Hüls 2022	cohort	PfiB / 1 or 2; Mod / 1 or 2; OxAz / 1 or 2; Jn / 1	NA (the unvaccinated number was mentioned; however, they did not follow outcomes in them)	3,696/3,895 (94.9%)	27.57 (12.09)	996 (45.9%)	280 of the 2172 participants (13%) (both vaccinated and unvaccinated) 259 (93%) (vaccinated)	NA	1 (0.1%)	Bell's palsy	NA	NA	NA	1	NA	NA	NA	Down syndrome (100%); participants had 1.5 comorbidities (SD = 1.4), with thyroid disorders (1050 participants (53%)), obstructive sleep apnea (545 (29%)), and obesity (546 (29%)) being the most common comorbidities.	NA	NA	NA	NA	NA	NA
Frontera 2022	cohort#	PfiB / 1 or 2;	none	306,907,697/306,907,697 (100%)	Total vaccinated: 50	63,945,188 (71%)	NA	NA	Total: 1846	Bell's palsy	NA	NA	NA	NA	NA	NA	NA	N/A	NA	NA	NA	NA	NA	

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paraclitics	Treatment	Outcome	Recurrence	
		CoronaVac/1 or 2; Convidectia / NA																						
Tamaki 2021	cross-sectional	NA	SARS-CoV-2 infection	63,551/127,102 (50%)	NA	NA	no (in the vaccinated group)	NA	NA	Bell's palsy	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Walker 2022 ^Δ	SCCS	Mod / 1	other SARS-CoV-2 vaccines	255,446/255,446 (100%)	34 (27–45) [§]	36 (46%)	NA	NA	78 (0.03%)	Bell's palsy	NA	NA	NA	1	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Ab Rahman 2022	SCCS	PfIB / 1 or 2; CoronaVac / 1 or 2; OxAz / 1 or 2	SARS-CoV-2 vaccines	35,201,509/35,201,509 (100%)	50.1 (15.2)	10,282,321 (50.9%)	NA	NA	PfIB: 27 (<0.1%) OxAz: 5 (<0.1%) Corona Vac: 21 (<0.1%)	Bell's palsy	NA	NA	NA	PfIB, dose 1: 17, dose 2: 11; CoronaVac, dose 1: 12, dose 2: 9; OxAz, dose 1: 4, dose 2: 1	various - all within 21 days	NA	NA	NA	NA	NA	NA	NA	NA	NA
Kaulen 2022	case series	PfIB / 1 or 2; Mod / 1 or 2; OxAz / 1 or 2; Jn / 1	NA	21/21 (100%)	50 (22–86) [§]	16 (76%)	no (at inclusion, SARS-CoV-2 infection was ruled out with polymerase chain reaction)	negative	1 (100%)	Bell's palsy	NA	NA	NA	NA	NA	NA	NA	NA	NA	brain MRI: T2-weighted hyperintensities of the facial nerve. CSF: mild lymphocytic pleocytosis (6/μl and 7/μl) and oligoclonal bands were positive in the CSF but not the serum	oral prednisolone	discharged; full and partial recovery in 5 (24%) and 15 (71%) patients, respectively	none	

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paradignics	Treatment	Outcome	Recurrence
																				(type 2); Autoimmune neuropathy panel: negative			
Burrows 2021	case report	PfIB / 2	NA	1/1 (100%)	61	0	NA (However, negative test for COVID-19 antibodies)	NA	1 (100%)	Bell's palsy (2 discrete contralateral Bell's palsies)	first episode: right; second episode: left.	first episode: none; second episode: dribbling and dysphagia	first episode: right-sided lower motor neuron facial palsy, no forehead movement, incomplete eye closure; second episode: severe left-sided facial nerve palsy of House Brackmann grade 4 with incomplete left eye closure	1 and 2	dose 1: 5 hours; dose 2: 2 days	reactivation of the herpes virus within the CNS (no prior or present herpes infection was mentioned)	negative	HTN, DLP, and insulin-dependent type 2 DM	amlodipine, ezetimibe, Lantus, and NovoRapid	lab data: normal; head CT: normal	first episode: prednisolone 60 mg daily with a 4-week subsequent weaning dose; second episode: 14-day course of prednisolone 60 mg daily	first episode: completely resolved; second episode: greatly improved	none
Cellina 2022	case report	Mod / 1	NA	1/1 (100%)	35	1 (100%)	NA	negative	1 (100%)	Bell's palsy confirmed clinically and by imaging	left	left laterocervical pain and stiffness, followed by the sensation of not holding liquids properly in the mouth	left facial droop with a slight difficulty in speaking and eating, inability to close the ipsilateral eye completely	1 (Mod)	12 hours	NA	negative	negative	NA	contrast-enhanced brain MRI 12 days after the vaccination: confirmed Bell's palsy and a subtle enhancement of the left facial nerve	prednisolone 50 mg daily for two weeks	discharged; on day 19 after injection: complete resolution	NA

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paradignics	Treatment	Outcome	Recurrence
Colella 2021	case report	PfIB / 1	NA	1/1 (100%)	37	0	no	negative	1 (100%)	Bell's palsy	left	malaise, fatigue, and headache ; left-sided laterocervical pain irradiating ipsilaterally to the mastoid, ear, and retro-maxillary region; unilateral muscle weakness	left-sided facial droop paresis, flattening of forehead's skin and marionette line (labial-buccal sulcus) ipsilaterally as well as mild flattening of the nasolabial fold; lagophthalmos and mild labial hypomobility; moderate Bell's sign (failure to close the eye on the affected side with exposure of the sclera)	1 (PfIB)	5 days	NA	NA	negative	NA	NA	prednisone 50 mg daily, eye drops (artificial tears), and eye dressing at night	discharged; the clinical signs worsened and progressed to complete paralysis within 2 weeks and were accompanied by severe pain; one month later: partial resolution	NA
Gómez de Terreros Caro 2021	case report	PfIB / 1	NA	1/1 (100%)	50	0	no	negative	1 (100%)	Bell's palsy	left	NA	facial droop, effacement of the nasolabial fold, and flaccidity on the left side of the face; complete paralysis of the left side of the face (the patient was unable	1	9 days	NA	negative	NA	NA	brain MRI: intracranial space-occupying lesions and ischemic events ruled out.	prednisone 60 mg daily for 7 days, subsequently tapered to 30 mg daily for 7 days and 15 mg daily for the next 7 days, with a total of 21 days of treatment; B-complex vitamins	discharged; one month later: partial resolution	NA

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paradignics	Treatment	Outcome	Recurrence
Martin - Villares 2022	case report	Mod / 1	NA	1/1 (100%)	34	1 (100%)	NA	NA	1 (100%)	Bell's palsy	right	right facial pain	to raise his eyebrow, close his left eye, or lift the labial commissure); effacement of frontal wrinkles	1	2 days	positive IgG Varicella Zoster Virus (VZV) Antibodies; history of Bell's palsy in the first pregnancy	positive	NA	NA	SARS-CoV-2 PCR: negative; and IgG Varicella Zoster Virus (VZV) Antibodies: positive; lymphocytosis; brain MRI: normal study; Nerve conduction studies: axonal facial neuropathy with a drop of CMAP 82% for mandibular branch, 66% for nasalis branch and 80% for zygomatic branch compared to the contralateral branch	deflazacort 30 mg daily, eye support, and facial rehabilitation	full recovery after 1 month	no

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paraclinicals	Treatment	Outcome	Recurrence
Mason 2021	case report	Mod / 1	NA	1/1 (100%)	35	1 (100%)	NA	NA	1 (100%)	bilateral Bell's palsy (mentioned to be quite rare)	bilateral	right facial weakness with associated occipital headaches, difficulty with speech, swallowing, mild right arm weakness ;	right facial asymmetry; inability to close the ipsilateral eye completely;	1	4 weeks	NA	NA	NA	NA	normal brain MRI, CBC, EMG-MCV, Lyme disease antibody, Covid-19 PCR; CSF: mild protein elevation	IV methylprednisolone 500 mg BD for 3 days and 400 mg of acyclovir QID	significant improvement by day 3 of admission	NA
Obermann 2021	case report	PfIB / 1	NA	1/1 (100%)	21	1 (100%)	NA	NA	1 (100%)	Bell's palsy confirmed clinically and by imaging	right	slight tingling sensation on the right	right facial nerve palsy	1	2 days	NA	NA	NA	NA	brain MRI: normal; CSF: normal; negative Herpes simplex type 1 (HSV), varicella-zoster-virus (VZV), measles virus, and Borrelia antibodies; negative SARS-CoV-2 PCR; negative, however, SARS-CoV-2 antibodies against the S1-protein: detectable in blood and CSF	prednisolone 100 mg daily over 5 days	discharged at 3 days of admission and started improvement	NA

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paradignics	Treatment	Outcome	Recurrence
Pothia wala 2021	case report	Mod / 2	NA	1/1 (100%)	46	0	no	none	1 (100%)	Bell's palsy	right	ageusia, tinnitus in the right ear	isolated right lower motor neuron facial nerve palsy; loss of right nasolabial fold, inability to close right eye completely	2	13 days	NA	negative	negative	none	NA	acyclovir and prednisone	discharged	NA
Repajic 2021	case report	PfIB / 2	NA	1/1 (100%)	57	1 (100%)	no	NA	1 (100%)	Bell's palsy	left	general malaise, ageusia, soreness behind the left ear above the jaw;	isolated left facial nerve palsy, facial droop; inability to close the left eye completely	2	36 hours	NA	positive	HTN and Bell's Palsy (three previous episodes, 2 (in 2003 and 2018) on the right and 1 (in 2013) on the left)	Losartan 50 mg daily; prednisone (responded well after each episode of Bell's palsy)	NA	prednisone and an antiviral agent (name not mentioned)	discharged	none
Tahir 2021	case report	Jn / 1	NA	1/1 (100%)	44	1 (100%)	NA	NA	1 (100%)	Bell's palsy and transverse myelitis	NA	worsening back pain associated with nausea and urinary retention; numbness and weakness in the lower extremities; low-grade fever; chills, and body aches	facial nerve palsy	1	NA-probably less than 20 days	NA	negative	negative	NA	negative SARS-CoV-2 PCR; CSF: normal; lab tests: normal; brain MRI: normal	pulse dose of methylprednisolone for 10 days and 5 sessions of plasma exchange	discharged; numbness, urinary retention, and Bell's palsy resolved over 10 days of treatment	NA
Yu 2021	case report	CoronaVac / 1	NA	1/1 (100%)	36	1 (100%)	NA	NA	1 (100%)	Bell's palsy and keratoconjunctivitis	right	eye discomfort, with dryness and foreign-body sensation, especially	House-Brackmann grade 3 isolated right facial nerve palsy;	1	2 days	NA	positive	left-side Bell's palsy in 2003; recovered after 1 month of	prednisone and acupuncture (fully recovered Bell's	positive SARS-CoV-2 whole-virion IgM and IgG; lab tests: normal;	prednisone 40 mg daily for 1 week; artificial tears and fluorometolone eye drops	discharged; 2 month later symptoms significantly improved	none

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paraclinics	Treatment	Outcome	Recurrence
												in the right eye	right-sided facial droop, disappearing of the forehead wrinkle, and inability to close eyelid completely					treatment with prednisone and acupuncture	palsy, in 2003, after 1 month of treatment)	brain CT scan: normal	(Santen, Osaka, Japan) were prescribed QID; Acupuncture therapy was applied three times weekly beginning of day 9		
Iftikhar 2021	case report	Mod / 2	NA	1/1 (100%)	36	0	no prior history of any medical illness (not specifically mentioned)	negative	1 (100%)	Bell's palsy	left	weakness over the left side of the face; slight difficulty in speaking and eating, mild numbness and tingling of the left arm along with subjective weakness of the left upper limb.	isolated left facial nerve palsy; inability to close left eye completely, flattening of wrinkle lines above the left eyebrow; drooping of the left corner of the mouth; slightly decreased sensations on his left upper limb which spared the lower limbs	2	1 day	NA	negative	PMH: negative	NA	normal brain CT and MRI	oral prednisolone 60 mg daily for 1-week, artificial tears, eye care instructions	discharged; partial improvement after two weeks	NA
Ish 2021	case report	COVAXIN / 1	NA	1/1 (100%)	50	0	NA (there was no history of systemic disease, not specifically mentioned)	negative	1 (100%)	Bell's palsy	right	eye redness and watering for 3 days	lagophthalmos; loss of forehead wrinkling and nasolabial fold, and drooping of angle of	2	3 weeks	NA	NA	PMH: healthy/ FH: NA/ HH: NA	NA	NA	topical antibiotics for eyes with frequent use of lubricating drops; taping of the right eye was advised when sleeping.	discharged; partial improvement after 10 days	NA

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paradigns	Treatment	Outcome	Recurrence
													mouth of the right side.								The patient was also started on oral prednisolone at 1 mg/kg for 2 weeks.		
Musatto 2022	case report	PfIB / 1	NA	1/1 (100%)	60	0	NA	NA	1 (100%)	Bell's palsy	left	left facial muscles weakness with involvement of the forehead,	inability to raise left eyebrow, and inability to close left eye; sensation and strength intact in bilateral upper and lower extremities	1 (PfIB)	2 days	NA	NA	HIV positive	elvitegravir, cobicistat, emtricitabine, tenofovir, and dolutegravir	lab tests: normal; ECG: normal	prednisone 60 mg daily for 6 days and valacyclovir 1000 mg TDS for 7 days; ophthalmic lubricating ointment hourly, artificial tears as needed, moisture goggles and suggested to tape eyelids nightly	discharged	NA
Nishizawa 2021	case report	Jn / 1	NA	1/1 (100%)	62	1 (100%)	NA	NA	1 (100%)	Bell's palsy	right	NA	near-complete paralysis of the right lower face and significant paralysis of the right upper face; right facial droop; incomplete eye closure, consistent with a House-Brackmann score 4	1	20 days	NA	NA	type 2 DM, HTN and DLP	brain MRI: normal	NA	NA	discharged	NA

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paradignics	Treatment	Outcome	Recurrence
González-Enríquez 2022	case report	Pfizer / 1	NA	1/1 (100%)	32	1 (100%)	no	negative	1 (100%)	Bell's palsy	right	malaise, fatigue, and headache, with high blood pressure-laterocervical pain	right facial paresis, absence of forehead wrinkles, lip-buccal sulcus and nasolabial fold; spasms of the facial and periorbital muscles; lagophthalmos and mild lip hypomobility	1	<3 hours	idiopathic	negative	Rheumatoid arthritis, fibromyalgia	normal lab tests-normal brain CT	prednisone, gabapentin and topiramate-artificial tears-myofunctional therapy of the facial muscles	full recovery after 15 days	no	
Khuroobi 2021	case report	Viral vector vaccine (name NA)	NA	1/1 (100%)	42	0	no	negative	1 (100%)	Bell's palsy	right	negative	right facial nerve palsy	1	2 days	autoimmune nerve injury	negative	negative	normal lab tests-normal brain MRI	prednisone 1mg/kg/day for 8 days along with eye protection	full recovery after 10 days. The patient received the second dose on the 6th week. A 3-month follow-up was normal.	no	
Poudel 2022	case report	Moderna / 1	NA	1/1 (100%)	17	1 (100%)	NA	negative	1(100%)	Bell's palsy	left	negative	left-sided facial muscle weakness	1	Within 24 hours	NA	negative	N/A	NA	oral prednisolone 50 mg once a day for three days and tapered by 10 mg every 4th day over two weeks period	recovered after five weeks	no	
Mirmosayyeb 2022	case report	Sputnik V / 1	NA	2/2 (100%)	42.5 (21.9)	1 (50%)	no - (case 2) NA	negative - negative	2 (100%)	Bell's palsy (clinically)	left - left	pain in the injection site, fatigue, weakness, low-grade fever, numbness of the left	facial nerve hemiparesis, normal cerebellar examination, normal	1 - 1	3 days - 6 days	NA	negative - negative	negative - controlled DM	brain MRI: normal - (case 2): NA	prednisone 1 mg/kg/day for 7 days, tapered within 2 weeks. virabex, valacyclo	recovered facial immobility after 10 days. Remained mild pulsating pain in the sternocleid	no - no	

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paradigns	Treatment	Outcome	Recurrence			
												side of the tongue, intact taste sensation, unable to close the left eye, shifting the left side of the upper and lower lip while chewing, laughing, or speaking, sharp pain along sternocleidomastoid muscle with an ipsilateral radiation to ear, mastoid, and retroauricular region - (Case 2) hyperthermia, myalgia, pain in the injection site, left facial sudden weakness, difficulty in closing left eye, tingling sensation on the tongue and lips, left-sided mouth droop, inability to smile correctly, drooling, decreased taste sensation, slurring of speech, tearing, inability to chew correctly, inability to	vital signs, afebrile. - (case 2) left facial muscle paresis, inability to close the left eye completely. No other neurologic deficits, normal vital signs.											vir 1000 mg twice a day. - (case 2) prednisone 50 mg (possibly 1 mg/kg/day) for 7 days, tapered within 2 weeks, valacyclovir 1000 mg twice a day	domastoid region. - (case 2) partial improvement of symptoms after 7 days and full recovery following further investigation (the last day of follow up is not mentioned)	

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paradignics	Treatment	Outcome	Recurrence
												move the left eyebrow.											
Corrêa 2021	case report	OxAz / 1	NA	3/3 (100%)	57 (13)	0	case 2: no	negative	1 (33%)	Bell's palsy confirmed clinically and by imaging	left	case 2: pain in the left ear, associated with left facial muscles weakness, accompanied by paresis of the left forehead's muscles, as well as left lagophthalmos and labial hypomobility, compatible with left peripheral facial nerve palsy,	case 2: paresis of the left forehead's muscles, left lagophthalmos and labial hypomobility	1	case 2: 7 days	NA	negative	case 2: negative	NA	case 2: brain MRI: normal; lab tests: normal; CSF: normal	case 2: oral prednisone 60 mg daily	case 2: discharged; full recovery after 7 days of treatment	NA
Hamid 2022	case report	PfIB / 1 or 2	NA	3/3 (100%)	23.3 (3.5)	1 (33.3%)	NA - NA - NA	negative - negative - negative	3/3 (100%)	facial paralysis	right - left - right	case one: lagophthalmos, and headache compatible with facial palsy - case two: left-sided cervicogenic headache - case three: dizziness, limitation of his right eye movement in lateral gaze, binocular diplopia, headache	case one: NA - case two: left-sided hemifacial paralysis - case three: both right sided facial palsy and right lateral rectus palsy.	case one: 1 - case two: 1 - case three: 2	case one: less than 24 hours - case two: 2 months - case three: 2 days	NA	NA	negative - negative - negative	NA - NA - NA	case one: normal CBC, MRI: normal - case two: thyroid hormone normal. CSF protein, cellularity, viral pathogen PCR panel, and glucose levels: normal, CSF culture: negative, MRI: linear and non-mass-like gadoliner	case one: prednisolone (dose NA) - case two: oral prednisone (dose NA) - case three: High-dose intravenous methylprednisolone (1gr/day for 10 days)	case one: NA - case two: partial response - case three: complete response	NA

Author, year	Design	Vaccine type(s)/	Control group	Sample size: SARS-CoV-2-vaccinated / Total (%)	Age, mean (SD)	Female, n. (%)	Prior SARS-CoV-2 infection	Herpes Zoster infection (past or present)	Bell's palsy, n (%)	Diagnosis as mentioned by the article	Laterality	concomitant signs and symptoms	Initial physical examination	After which dose the facial palsy occurred?	Duration between vaccination facial	Suspected underlying pathophysiology	History of facial palsy	PMH	Drug history	Paradigns	Treatment	Outcome	Recurrence
																				Am enhancement in the internal auditory canal portion of the left facial nerve - case three: CSF normal, CSF culture: negative, Cranial MRI: vivid and non-nodular gadolinium enhancement in the labyrinth portion of the right facial nerve extended into the right geniculate ganglion			

CVac, CoronaVac; F, female; IQR, interquartile range; Jn, Janssen; Mod, Moderna; NA, not available; OxAz, Oxford/AstraZeneca; PfiB, Pfizer/BioNTech; RCT, randomized controlled trial; SCCS, self-controlled case series; SD, standard deviation.

* Mean (range)

† Median (range)

‡ varied between trials- the majority between 18-55

§ Median (IQR)

|| in individuals reporting Bell's palsy

¶ El-Shitany 2021: <60y: 299 (65.7%); ≥60y: 156 (34.3%)/ <65: 4001 (18.8%); Bardenheier 2021: 65-74y: 4981 (23.5%); 75-84y: 5912 (27.9%) ; ≥85y: 6328 (29.8%)

Nosedá 2021: Data from the VigiBase database accessed as of May 16, 2021; Patone 2021: data from the English National Immunisation (NIMS) database; Frontera 2022: data from the VAERS accessed between January 1, 2021, and June 14, 2021; Li 2022: data from the SIDIAP database.

Δ This study also included individuals receiving Oxford/AstraZeneca but overlapped with other studies.

Table S9- Summary of the studies' characteristics (case reports and case series).

Author, year	Design	Vaccine type doses	vaccinated (% total)	Mean age	Female (%)	Bell's palsy (%)
Kaulen 2022	case series	PfiB 1 or 2, Mod 1 or 2, OxAz 1 or 2, Jn 1	21/21 (100%)	50 (22–86) [§]	16 (76%)	1 (100%)
Burrows 2021	case report	PfiB 2	1/1 (100%)	61	0	1 (100%)
Cellina 2022	case report	Mod 1	1/1 (100%)	35	1 (100%)	1 (100%)
Colella 2021	case report	PfiB 1	1/1 (100%)	37	0	1 (100%)
Gómez de Terreros Caro 2021	case report	PfiB 1	1/1 (100%)	50	0	1 (100%)
Martin-Villares 2022	case report	Mod 1	1/1 (100%)	34	1 (100%)	1 (100%)
Mason 2021	case report	Mod 1	1/1 (100%)	35	1 (100%)	1 (100%)
Obermann 2021	case report	PfiB 1	1/1 (100%)	21	1 (100%)	1 (100%)
Pothiawala 2021	case report	Mod 2	1/1 (100%)	46	0	1 (100%)
Repajic 2021	case report	PfiB 2	1/1 (100%)	57	1 (100%)	1 (100%)
Tahir 2021	case report	Jn 1	1/1 (100%)	44	1 (100%)	1 (100%)
Yu 2021	case report	CVac 1	1/1 (100%)	36	1 (100%)	1 (100%)
Iftikhar 2021	case report	Mod 2	1/1 (100%)	36	0	1 (100%)
Ish 2021	case report	COVAXIN 1	1/1 (100%)	50	0	1 (100%)
Mussatto 2022	case report	PfiB 1	1/1 (100%)	60	0	1 (100%)
Nishizawa 2021	case report	Jn 1	1/1 (100%)	62	1 (100%)	1 (100%)
González-Enríquez 2022	case report	PfiB 1	1/1 (100%)	32	1 (100%)	1 (100%)
Kharoubi 2021	case report	Viral vector vaccine (name NA)	1/1 (100%)	42	0	1 (100%)
Poudel 2022	case report	Mod 1	1/1 (100%)	17	1 (100%)	1 (100%)
Mirmosayyeb 2022	case report	Sputnik V 1	2/2 (100%)	42.5 (21.9)	1 (50%)	2 (100%)
Corrêa 2021	case report	OxAz 1	3/3 (100%)	57 (13)	0	1 (33%)
Hamid 2022	case report	PfiB 1 or 2	3/3 (100 %)	23.3 (3.5)	1 (33.3%)	3/3 (100%)

CVac: CoronaVac, Jn: Janssen, Mod: Moderna, NA: not available, OxAz: Oxford/AstraZeneca, PfiB, Pfizer/BioNTech